PPARα activators may play role for the regression of ventricular hypertrophy in hypertensive and hyperlipidemic patients [9]

Erol A.2024-07-222024-07-22200603069877http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19590[No abstract available]EnglishAntilipemic AgentsClinical TrialsEvidence-Based MedicineHumansHyperlipidemiasHypertensionHypertrophy, Left VentricularModels, CardiovascularPPAR alphaProcetofenTreatment Outcomefenofibrateperoxisome proliferator activated receptor alphaantilipemic agentfenofibrateperoxisome proliferator activated receptor alphablood pressure regulationheart muscle cellheart ventricle hypertrophyhumanhyperlipidemiahypertensionletterlipid metabolismlipoprotein metabolismnonhumanoxidative stresspriority journalremissionbiological modelclinical trialdrug potentiationevidence based medicineheart left ventricle hypertrophyhyperlipidemiahypertensionmetabolismtreatment outcomePPARα activators may play role for the regression of ventricular hypertrophy in hypertensive and hyperlipidemic patients [9]Letter10.1016/j.mehy.2005.12.001